Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Oncodrone awarded grant for OCD155 development
October 2015
SHARING OPTIONS:

AMSTERDAM—Anticancer company Oncodrone recently announced that it had received a €2.5-million (approximately $2.8 million) grant from Eurostars, a joint program between EUREKA and the European Commission. The grant will support the development of OCD155, Oncodrone’s lead drug for the treatment of prostate cancer, enabling the company to progress the drug through preclinical development toward clinical trials and further explore its mechanism of action, which will be done in a Dutch-Danish-German-Swiss consortium, including the partners Radboud UMC and Leiden UMC. OCD155 blocks epithelial to mesenchymal transition in cancers, thereby halting tumor progression and, in the lab, has been shown to reduce tumor burden, reduce tumors’ ability to spread and treat advanced stages of disease.
 
Henk Viëtor, CEO of Oncodrone, noted: “I’m delighted about this crucial grant, that allows us to further develop our novel approach to treating prostate cancer towards testing in humans.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.